Ukr.Biochem.J. 2019; Volume 91, Issue 5, Sep-Oct, pp. 25-33

doi: https://doi.org/10.15407/ubj91.05.025

Influence of human HB-EGF secreted form on cells with different EGFR and ErbB4 quantity

O. I. Krynina, N. V. Korotkevych, A. J. Labyntsev,
S. I. Romaniuk, D. V. Kolybo, S. V. Komisarenko

Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv;
e-mail: olyakrynina@gmail.com

Received: 18 July 2019; Accepted: 13 August 2019

HB-EGF is one of the most potent ligands of EGFR and ErbB4 receptors. This growth factor plays a pivotal role in many cellular processes, but its effect differs from one cell type to another and remains not fully understood. The aim of this work was to investigate the dependence between the rate of HB-EGF mediated cell proliferation and activation of EGFR and ErbB4 receptors. Therefore, the effects of human recombinant sHB-EGF (rsHB-EGF) on the proliferation of cell lines with different EGFR and ErbB4 quantity and ratio, as well as activation of the MARK-cascade p38 and ERK1/2 (p42/44) kinases, were analyzed. For comparison, a similar study of the effect of native sHB-EGF secreted by human histiocytic lymphoma cells U937 during co-cultivation with different cell lines was performed.
It was proved that cell proliferation in response to sHB-EGF depends not only on the quantity but also on the ratio of EGFR and ErbB4. It was shown that signaling through ErbB4 is associated with activation of p38 kinase and signaling through EGFR associated with activation of ERK1/2 (p42/44) kinase. We assume the existence of two different mechanisms for sHB-EGF-mediated stimulation of cell proliferation, and the simultaneous launch of these mechanisms provides a maximal proliferative response. The results of this study support the feasibility of creating anti-proliferative drugs that target ErbB4.

Keywords: , , , , ,


References:

  1. Murphrey MB, Varacallo M. Biochemistry, Epidermal Growth Factor Receptor. Treasure Island (FL): StatPearls Publishing, 2019.
  2. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science. 1991 Feb 22;251(4996):936-9. PubMed, CrossRef
  3. Higashiyama S, Lau K, Besner GE, Abraham JA, Klagsbrun M. Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein. J Biol Chem. 1992 Mar 25;267(9):6205-12. PubMed
  4. Higashiyama S, Nanba D. ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk. Biochim Biophys Acta. 2005 Aug 1;1751(1):110-7.  PubMed, CrossRef
  5. Singh B, Carpenter G, Coffey RJ. EGF receptor ligands: recent advances. F1000Res. 2016 Sep 8;5. pii: F1000 Faculty Rev-2270. PubMed, PubMedCentral, CrossRef
  6. Higashiyama S, Abraham JA, Klagsbrun M. Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate. J Cell Biol. 1993 Aug;122(4):933-40. PubMed, PubMedCentral, CrossRef
  7. Lindsey S, Langhans SA. Epidermal growth factor signaling in transformed cells. Int Rev Cell Mol Biol. 2015;314:1-41.  PubMed, PubMedCentral, CrossRef
  8. Hirata Y, Ogasawara N, Sasaki M, Mizushima T, Shimura T, Mizoshita T, Mori Y, Kubota E, Wada T, Tanida S, Kataoka H, Kamiya T, Higashiyama S, Joh T. BCL6 degradation caused by the interaction with the C-terminus of pro-HB-EGF induces cyclin D2 expression in gastric cancers. Br J Cancer. 2009 Apr 21;100(8):1320-9. PubMed, PubMedCentral, CrossRef
  9. Ozeki K, Tanida S, Morimoto C, Inoue Y, Mizoshita T, Tsukamoto H, Shimura T, Kataoka H, Kamiya T, Nishiwaki E, Ishiguro H, Higashiyama S, Joh T. Telmisartan inhibits cell proliferation by blocking nuclear translocation of ProHB-EGF C-terminal fragment in colon cancer cells. PLoS One. 2013;8(2):e56770. PubMed, PubMedCentral, CrossRef
  10. Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014 Jan;79:34-74.  PubMed, CrossRef
  11.  Iwamoto R, Mine N, Mizushima H, Mekada E. ErbB1 and ErbB4 generate opposing signals regulating mesenchymal cell proliferation during valvulogenesis. J Cell Sci. 2017 Apr 1;130(7):1321-1332. PubMed, CrossRef
  12. Liu Y, Song L, Ni H1, Sun L, Jiao W, Chen L, Zhou Q, Shen T, Cui H, Gao T, Li J. ERBB4 acts as a suppressor in the development of hepatocellular carcinoma. Carcinogenesis. 2017 Apr 1;38(4):465-473.  PubMed, CrossRef
  13. Hoesl C, Röhrl JM, Schneider MR, Dahlhoff M. The receptor tyrosine kinase ERBB4 is expressed in skin keratinocytes and influences epidermal proliferation. Biochim Biophys Acta Gen Subj. 2018 Apr;1862(4):958-966. PubMed, CrossRef
  14. Xu J, Gong L, Qian Z, Song G, Liu J. ERBB4 promotes the proliferation of gastric cancer cells via the PI3K/Akt signaling pathway. Oncol Rep. 2018 Jun;39(6):2892-2898. PubMed, CrossRef
  15. Strober W. Trypan blue exclusion test of cell viability. Curr Protoc Immunol. 2001; 21(1): 1-2. PubMed, CrossRef
  16. Korotkevych NV, Kolybo DV, Labyntsev AJ. Obtaining recombinant secretory form of human HB-EGF and perspectives of its application in biotechnology. Biotechnologia Acta. 2010; 3(4): 44-54. (In Ukrainian).
  17.  Korotkevych NV, Labyntsev AJ, Kolybo DV, Komisarenko SV. Obtaining and characterization of recombinant fluorescent derivatives of soluble human HB-EGF. Biotechnologia Acta. 2014; 7(2): 46-53. (In Ukrainian). CrossRef
  18. Schägger H, von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem. 1987 Nov 1;166(2):368-79. PubMed, CrossRef
  19. Lin CC, Lee IT, Hsu CH, Hsu CK, Chi PL, Hsiao LD, Yang CM. Sphingosine-1-phosphate mediates ICAM-1-dependent monocyte adhesion through p38 MAPK and p42/p44 MAPK-dependent Akt activation. PLoS One. 2015 Mar 3;10(3):e0118473.  PubMed, PubMedCentral, CrossRef
  20. Junttila TT, Sundvall M, Määttä JA, Elenius K. Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc Med. 2000 Oct;10(7):304-10. PubMed, CrossRef
  21. Zheng Y, Li X, Qian X, Wang Y, Lee JH, Xia Y, Hawke DH, Zhang G, Lyu J, Lu Z. Secreted and O-GlcNAcylated MIF binds to the human EGF receptor and inhibits its activation. Nat Cell Biol. 2015 Oct;17(10):1348-55. PubMed, PubMedCentral, CrossRef
  22. Liao HW, Hsu JM, Xia W, Wang HL, Wang YN, Chang WC, Arold ST, Chou CK, Tsou PH, Yamaguchi H, Fang YF, Lee HJ, Lee HH, Tai SK, Yang MH, Morelli MP, Sen M, Ladbury JE, Chen CH, Grandis JR, Kopetz S, Hung MC. PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. J Clin Invest. 2015 Dec;125(12):4529-43. PubMed, PubMedCentral, CrossRef
  23. Rauf F, Festa F, Park JG, Magee M, Eaton S, Rinaldi C, Betanzos CM, Gonzalez-Malerva L, LaBaer J. Ibrutinib inhibition of ERBB4 reduces cell growth in a WNT5A-dependent manner. Oncogene. 2018 Apr;37(17):2237-2250.  PubMed, PubMedCentral, CrossRef

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.